This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast And Market Analysis Event-Driven Update

Table 2: Treatment Guidelines for Rheumatoid Arthritis 21

Table 3: Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market 23

Table 4: Treatment Guidelines for Rheumatoid Arthritis 27

Table 5: Product Profile - Enbrel 28

Table 6: 10 year Open-label Safety and Efficacy Trial of Enbrel: Efficacy Results at 11 years for Completers 29

Table 7: 10 year Open-label Safety and Efficacy Trial of Enbrel: Safety Results Overall 30

Table 8: Enbrel SWOT Analysis, 2012 32

Table 9: Product Profile - Humira 33

Table 10: Humira SWOT Analysis, 2012 35

Table 11: Product Profile - Remicade 37

Table 12: Remicade SWOT Analysis, 2012 39

Table 13: Product Profile - Simponi 41

Table 14: Simponi SWOT Analysis, 2012 43

Table 15: Product Profile - Cimzia 45

Table 16: Cimzia SWOT Analysis, 2012 47

Table 17: Product Profile - Orencia 48

Table 18: Orencia SWOT Analysis, 2012 50

Table 19: Product Profile - Actemra/RoActemra 52

Table 20: Actemra/RoActemra SWOT Analysis, 2012 54

Table 21: Product Profile - Rituxan 56

Table 22: Rituxan SWOT Analysis, 2012 58

Table 23: Product Profile - Methotrexate 60

Table 24: Methotrexate SWOT Analysis, 2012 61

Table 25: Summary of Minor Therapeutic Classes, 2012 62

Table 26: Overall Unmet Needs - Current Level of Attainment 63

Table 27: Clinical Unmet Needs - Gap Analysis, 2012 66

Table 28: Rheumatoid Arthritis - Phase Pipeline, 2012 68

Table 29: Comparison of Therapeutic Classes in Development for RA, 2012 69

Table 30: Product Profile - Tofacitinib 70

Table 31: Clinical Trial Locations by Country for Tofacitinib 71

Table 32: ORAL Standard ACR 20 Responses for Tofacitinib vs. Placebo vs. Humira at Month 6 71

Table 33: ORAL Step ACR 20, 50, 70 Responses for Tofacitinib vs. Placebo at Month Six 72

Table 34: Efficacy Issues Regarding Tofacitinib Determined by FDA Advisory Panel, May 2012 72

Table 35: Safety Issues Regarding Tofacitinib Determined by FDA Advisory Panel, May 2012 73

Table 36: Tofacitinib Clinical Trial Mortalities as of September 29, 2011 74

Table 37: Tofacitinib SWOT Analysis, 2012 75

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs